Drug-penetration gradients associated with acquired drug resistance in patients with tuberculosis

Keertan Dheda, Laura Lenders, Gesham Magombedze, Shashikant Srivastava, Prithvi Raj, Erland Arning, Paula Ashcraft, Teodoro Bottiglieri, Helen Wainwright, Timothy Pennel, Anthony Linegar, Loven Moodley, Anil Pooran, Jotam G. Pasipanodya, Frederick A. Sirgel, Paul D. Van Helden, Edward K Wakeland, Robin M. Warren, Tawanda Gumbo

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

Rationale: Acquired resistance is an important driver of multidrugresistant tuberculosis (TB), even with good treatment adherence. However, exactly what initiates the resistance and how it arises remain poorly understood. Objectives: To identify the relationship between drug concentrations and drug susceptibility readouts (minimuminhibitory concentrations [MICs]) in the TB cavity. Methods: We recruited patients with medically incurable TB who were undergoing therapeutic lung resection while on treatment with a cocktail of second-line anti-TB drugs. On the day of surgery, antibiotic concentrations were measured in the blood and at seven prespecified biopsy sites within each cavity. Mycobacterium tuberculosis was grown from each biopsy site,MICs of each drug identified, and whole-genome sequencing performed. Spearman correlation coefficients between drug concentration and MIC were calculated. Measurements and Main Results: Fourteen patients treated for a median of 13 months (range, 5-31 mo) were recruited. MICs and drug resistance-associated single-nucleotide variants differed between the different geospatial locations within each cavity, and with pretreatment and serial sputum isolates, consistent with ongoing acquisition of resistance. However, pretreatment sputum MIC had an accuracy of only 49.48% in predicting cavitary MICs. There were large concentration-distance gradients for each antibiotic. The location-specific concentrations inversely correlated with MICs (P,0.05) and therefore acquired resistance. Moreover, pharmacokinetic/pharmacodynamic exposures known to amplify drug-resistant subpopulations were encountered in all positions. Conclusions: These data inform interventional strategies relevant to drug delivery, dosing, and diagnostics to prevent the development of acquired resistance. The role of high intracavitary penetration as a biomarker of antibiotic efficacy, when assessing new regimens, requires clarification.

Original languageEnglish (US)
Pages (from-to)1208-1219
Number of pages12
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume198
Issue number9
DOIs
StatePublished - Nov 1 2018

Keywords

  • acquired drug resistance
  • drug gradient
  • lung cavity
  • sputum MIC
  • whole-genome sequencing

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Fingerprint Dive into the research topics of 'Drug-penetration gradients associated with acquired drug resistance in patients with tuberculosis'. Together they form a unique fingerprint.

  • Cite this

    Dheda, K., Lenders, L., Magombedze, G., Srivastava, S., Raj, P., Arning, E., Ashcraft, P., Bottiglieri, T., Wainwright, H., Pennel, T., Linegar, A., Moodley, L., Pooran, A., Pasipanodya, J. G., Sirgel, F. A., Van Helden, P. D., Wakeland, E. K., Warren, R. M., & Gumbo, T. (2018). Drug-penetration gradients associated with acquired drug resistance in patients with tuberculosis. American Journal of Respiratory and Critical Care Medicine, 198(9), 1208-1219. https://doi.org/10.1164/rccm.201711-2333OC